New York, Feb 24, 2026, 08:49 EST — Premarket
- BillionToOne dropped roughly 16% last session, ending the day at $72.10.
- Diagnostics maker reports Q4 and full-year numbers March 4.
- Investors are looking for evidence that demand remains steady while the company ramps up its prenatal and oncology testing operations.
BillionToOne, Inc dropped 15.7% in the last session. Shares settled at $72.10 after a steep late drop, putting the recently listed diagnostics company near the bottom of the day’s performers.
The timing of the drop is notable; BillionToOne is still a newcomer to public markets, and the next major update is just around the corner. On March 4, the company will release its fourth-quarter and full-year results. Investors are waiting for more detail on volumes, pricing, and costs.
The last press release from BillionToOne went up on Feb. 17, outlining plans to report results March 4. So traders on Monday were left looking to positioning and the wider risk backdrop for answers behind the move.
Based in Menlo Park, California, the company offers molecular diagnostic tests for prenatal screening and cancer, relying on its technology to analyze small pieces of DNA. Its lineup faces stiff competition, both from other prenatal screening providers and firms focused on liquid biopsy.
Stocks slipped in the U.S. on Monday, but BillionToOne tumbled much harder than the broad indexes. Smaller healthcare stocks, which had managed to stay resilient for months, saw investors cashing out.
Results land in just over a week, and investors are zeroing in on test volumes and the mix. Another key question: how fast can the company ramp up in oncology and still hang on to margins? Reimbursement will matter as well—coverage decisions have a way of shifting diagnostics revenue fast.
Back in January, the company set its sights on 2026, projecting revenue between $415 million and $430 million, and targeting positive GAAP operating income for that year. Investors took note. But after Monday’s drop, it looks like some are recalibrating—maybe much of that optimism was already baked into the stock.
Competition is biting, too. Prenatal screening pits companies against deep-pocketed rivals, while over in liquid biopsy, the space resembles a land grab as payers and health systems turn up the heat on both evidence and price.
This isn’t just chatter. The real test lands March 4, when the company releases its report and holds the conference call—management will need to back up those growth claims with hard numbers and address any slips in demand, pricing, or how they’re getting things done.
